MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 05-30-2026
ACADIA Pharmaceuticals ROA Ratio 2011-2026 | ACAD
Annual ROA Ratio ACADIA Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 25.0 | 19.07 | -8.18 | - | -23.98 | -35.98 | -30.04 | -45.39 | -75.27 | -48.36 | -74.11 | -28.41 | -20.07 | -19.2 | -70.89 | 39.43 | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 39.43 | -75.27 | -26.43 |
Quarterly ROA Ratio ACADIA Pharmaceuticals
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9.47 | 12.6 | 10.86 | 10.62 | -1.36 | -4.54 | -14.76 | -22.25 | -30.05 | -36.38 | -29.82 | -29.82 | -31.83 | -32.34 | -23.02 | -25.4 | -34.2 | -33.53 | -35.98 | -34.22 | -28.76 | -30.39 | -30.04 | -35.39 | -41.53 | -46.23 | -45.39 | -51.18 | -56.64 | -62.47 | -75.27 | -71.38 | -67.17 | -62.34 | -48.36 | -54.97 | -59.74 | -64.78 | -74.11 | -62.19 | -52.27 | -41.13 | -28.41 | -26.07 | -24.11 | -22.31 | -20.07 | -19.97 | -16.52 | -16.71 | -19.2 | -29.43 | -43.03 | -58.45 | -70.89 | -15.81 | -20.41 | -18.16 |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 12.6 | -75.27 | -34.26 |
ROA Ratio of other stocks in the Biotechnology industry
| Issuer | ROA Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
FSD Pharma
HUGE
|
-241.53 | - | 5743.5 % | $ 69.7 M |  Canada |
 |
MorphoSys AG
MOR
|
-20.13 | - | 2.43 % | $ 254 M |  Germany |
 |
Happiness Biotech Group Limited
HAPP
|
-22.19 | - | 1.35 % | $ 17.8 M |  China |
 |
Dynavax Technologies Corporation
DVAX
|
2.77 | - | - | $ 2.02 B |  USA |
 |
AgeX Therapeutics
AGE
|
-275.96 | - | -10.17 % | $ 12.2 K | USA |
 |
I-Mab
IMAB
|
7.43 | - | - | $ 866 M | China |
 |
Deciphera Pharmaceuticals
DCPH
|
-41.16 | - | - | $ 2.18 B | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
3.33 | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
23.87 | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
-142.36 | - | -13.47 % | $ 169 M | France |
 |
Alpine Immune Sciences
ALPN
|
-8.47 | - | - | $ 2.17 B | USA |
 |
ASLAN Pharmaceuticals Limited
ASLN
|
-179.56 | - | -14.27 % | $ 1.7 M |  Singapore |
 |
AstraZeneca PLC
AZN
|
8.97 | - | - | $ 96.9 B |  Britain |
 |
CureVac N.V.
CVAC
|
20.2 | - | - | $ 867 M | Germany |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-53.39 | - | -1.52 % | $ 24.7 M | USA |
 |
Athira Pharma
ATHA
|
-114.6 | - | - | $ 269 M | USA |
 |
BiondVax Pharmaceuticals Ltd.
BVXV
|
-40.14 | - | 0.74 % | $ 768 M |  Israel |
 |
Abcam plc
ABCM
|
-0.8 | - | - | $ 4.9 B | Britain |
 |
Galera Therapeutics
GRTX
|
2071.28 | - | -32.59 % | $ 7.61 M | USA |
 |
Midatech Pharma plc
MTP
|
-35.12 | - | -18.52 % | $ 27.3 M | Britain |
 |
Affimed N.V.
AFMD
|
-109.04 | - | -34.95 % | $ 21.5 M | Germany |
 |
CRISPR Therapeutics AG
CRSP
|
-25.67 | $ 49.8 | -0.86 % | $ 4.48 B |  Schweiz |
 |
Институт стволовых клеток человека
ISKJ
|
4.82 | - | - | - |  Russia |
 |
Checkmate Pharmaceuticals
CMPI
|
-77.89 | - | - | $ 231 M | USA |
 |
Celyad Oncology SA
CYAD
|
-207.62 | - | - | $ 12.5 M |  Belgium |
 |
Berkeley Lights
BLI
|
-43.36 | - | -7.31 % | $ 87 M | USA |
 |
Celldex Therapeutics
CLDX
|
-44.38 | $ 31.27 | 4.37 % | $ 2.08 B | USA |
 |
Generation Bio Co.
GBIO
|
-56.95 | - | - | $ 344 M | USA |
 |
IMV
IMV
|
-121.19 | - | - | $ 13.1 M | Canada |
 |
Akero Therapeutics
AKRO
|
-30.52 | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
-31.09 | - | 0.23 % | $ 488 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-489.29 | - | - | $ 7.46 M | Israel |
 |
Cyclacel Pharmaceuticals
CYCCP
|
36.63 | - | -4.36 % | $ 27 M | USA |
 |
Freeline Therapeutics Holdings plc
FRLN
|
-102.69 | - | - | $ 384 M | Britain |
 |
Gracell Biotechnologies
GRCL
|
-36.68 | - | - | $ 3.37 B | China |
 |
Anika Therapeutics
ANIK
|
-5.72 | $ 14.72 | - | $ 211 M | USA |
 |
Advaxis
ADXS
|
-289.96 | - | -9.65 % | $ 45.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
-48.33 | - | 5.93 % | $ 314 M | Canada |
 |
Aeglea BioTherapeutics
AGLE
|
-19.95 | - | - | $ 1.01 B | USA |
|
Enlivex Therapeutics Ltd.
ENLV
|
53.1 | $ 0.67 | -6.8 % | $ 30.6 M | Israel |
 |
Applied Genetic Technologies Corporation
AGTC
|
-27.57 | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
-19.87 | - | 1.93 % | $ 17.4 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-103.3 | $ 2.84 | -0.35 % | $ 4.68 M | Israel |
|
Forte Biosciences
FBRX
|
-83.81 | $ 17.56 | 0.92 % | $ 227 M | USA |
 |
Esperion Therapeutics
ESPR
|
-4.87 | $ 3.15 | - | $ 655 M | USA |
 |
Aptose Biosciences
APTO
|
-254.37 | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
-97.25 | - | -39.0 % | $ 4.57 M | USA |
 |
Albireo Pharma
ALBO
|
-11.27 | - | -0.23 % | $ 916 M | USA |
 |
AlloVir
ALVR
|
-35.68 | - | 4.14 % | $ 49.1 M | USA |
 |
Allakos
ALLK
|
-119.89 | - | - | $ 28.6 M | USA |